Landaas & CO Abb Vie Inc. Transaction History

Landaas & CO

$327 Million
Q2 2024

A detailed history of Landaas & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Landaas & CO holds 4,702 shares of ABBV stock, worth $947,453. This represents 0.25% of its overall portfolio holdings.

Number of Shares

4,702

Previous 4,518 4.07%

Holding current value

$947,453

Previous $822,000 1.95%

% of portfolio

0.25%

Previous 0.27%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $28,481 - $33,259	184 Added 4.07%	4,702 $806,000
Q1 2024 May 09, 2024	SELL	$159.82 - $182.1 $141,440 - $161,158	-885 Reduced 16.38%	4,518 $822,000
Q4 2023 Feb 12, 2024	BUY	$137.6 - $154.97 $73,753 - $83,063	536 Added 11.01%	5,403 $837,000
Q2 2023 Aug 03, 2023	SELL	$132.51 - $164.9 $22,526 - $28,033	-170 Reduced 3.38%	4,867 $655,000
Q1 2023 May 10, 2023	SELL	$144.61 - $166.54 $28,922 - $33,308	-200 Reduced 3.82%	5,037 $802,000
Q4 2022 Feb 15, 2023	SELL	$138.31 - $165.87 $38,035 - $45,614	-275 Reduced 4.99%	5,237 $846,000
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $4,965 - $5,695	-37 Reduced 0.67%	5,512 $740,000
Q2 2022 Aug 09, 2022	BUY	$137.62 - $174.96 $9,633 - $12,247	70 Added 1.28%	5,549 $850,000
Q2 2021 Aug 17, 2021	SELL	$105.21 - $117.21 $10,521 - $11,721	-100 Reduced 1.79%	5,479 $617,000
Q1 2021 May 11, 2021	BUY	$102.3 - $112.62 $25,575 - $28,155	250 Added 4.69%	5,579 $604,000
Q3 2020 Nov 06, 2020	SELL	$85.91 - $100.83 $528,518 - $620,306	-6,152 Reduced 53.58%	5,329 $467,000
Q2 2020 Aug 04, 2020	BUY	$73.37 - $98.18 $7,337 - $9,818	100 Added 0.88%	11,481 $1.13 Million
Q4 2019 Feb 13, 2020	SELL	$72.13 - $90.25 $31,448 - $39,349	-436 Reduced 3.69%	11,381 $1.01 Million
Q3 2019 Oct 30, 2019	SELL	$62.98 - $75.72 $4,912 - $5,906	-78 Reduced 0.66%	11,817 $895,000
Q2 2019 Jul 29, 2019	SELL	$65.7 - $83.98 $12,745 - $16,292	-194 Reduced 1.6%	11,895 $865,000
Q1 2019 Apr 19, 2019	BUY	$77.14 - $90.79 $857,411 - $1.01 Million	11,115 Added 1141.17%	12,089 $974,000
Q1 2019 Apr 18, 2019	SELL	$77.14 - $90.79 $848,848 - $999,053	-11,004 Reduced 91.87%	974 $974,000
Q4 2018 Feb 05, 2019	SELL	$77.85 - $96.01 $7,084 - $8,736	-91 Reduced 0.75%	11,978 $1.1 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $711 - $790	8 Added 0.07%	12,069 $1.14 Million
Q2 2018 Aug 07, 2018	SELL	$89.78 - $106.23 $8,349 - $9,879	-93 Reduced 0.77%	12,061 $1.12 Million
Q1 2018 May 14, 2018	BUY	$92.01 - $123.21 $9,661 - $12,937	105 Added 0.87%	12,154 $1.15 Million
Q4 2017 Feb 06, 2018	SELL	$89.56 - $98.21 $71,200 - $78,076	-795 Reduced 6.19%	12,049 $1.17 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $897,153 - $1.15 Million	12,844	12,844 $1.14 Million

Others Institutions Holding ABBV

# of Institutions

3,760

Shares Held

1.28B

Call Options Held

13M

Put Options Held

9.83M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $356B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Landaas & CO , based on Form 13F filings with the SEC.

News

Stay updated on Landaas & CO with notifications on news.

Account